Canaccord Genuity Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $36
Canaccord Genuity analyst Sumant Kulkarni maintains ACADIA Pharmaceuticals (NASDAQ: ACAD ) with a Buy and raises the price target from $32 to $36.
Story updates
02:02:26 PM UTC
SquawkNews
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ: ACAD ) with a Buy and raises the price target from $32 to $35.
Canaccord Genuity analyst Sumant Kulkarni maintains ACADIA Pharmaceuticals (NASDAQ: ACAD ) with a Buy and raises the price target from $32 to $36.